site:pharmaphorum.com - Search Images

960 x 540 · jpeg
pharmaphorum.com
Adcendo licenses Multitude anti-TF ADC in $1bn+ deal | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Sanofi to invest €1bn in France to lift ‘health sovereignty’ | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
FDA launches innovation hub to spur rare disease R&D | pharmaphorum

960 x 540 · jpeg
pharmaphorum.com
AI firm Generate signs $1bn discovery deal with Novartis | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
ERS: GSK reveals data behind new asthma hope depemokimab | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
PBC drug choices rise in US with OK for Gilead's seladelpar | pharmaphorum

900 x 600 · jpeg
pharmaphorum.com
Novo Nordisk launches recycling programme for pen injectors | p…
1280 x 720 · jpeg
pharmaphorum.com
ACELYRIN acquires ValenzaBio, strengthens immunology position | pha…
960 x 540 · jpeg
pharmaphorum.com
Xtandi cleared by FDA for earlier-stage prostate cancer | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
FDA says yes to MSD’s 21-valent adult pneumococcal jab | pharmaphorum

960 x 540 · jpeg
pharmaphorum.com
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
Pharma’s climate change vulnerability and opportunity | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Levicept says non-opioid drug cuts arthritis pain in phase 2 | pharmaphorum

960 x 540 · jpeg
pharmaphorum.com
EU starts review of Enhertu in HER2-ultra-low breast cancer | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Roche trumpets potential ‘best-in-class’ obesity drug | pharmaphorum
900 x 600 · jpeg
pharmaphorum.com
Blockbusters in waiting: Clarivate's drugs to watch in 20…
1200 x 675 · jpeg
pharmaphorum.com
Legal win leads Amgen to at-risk launch of Eylea biosimilar | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
AbbVie gets continuous Parkinson's drug over the line in US | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Digital therapeutics firm Akili agrees $34 million takeover | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
Pfizer gets a leg up in RSV as FDA clears jab for all adults | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
The role of quality assurance in accelerating drug development for emerging therapies | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
Vaxcyte's pneumococcal vaccine win points to Prevnar battle | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
Lilly's Alzheimer's drug gets UK nod, but no NHS funding | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
Generative AI in clinical trials: Practical use cases and common concerns | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
BIO-Europe's 30th Anniversary Landmark Event in Stockholm | pharmaphorum
960 x 540 · jpeg
pharmaphorum.com
AbbVie’s 24-hour Parkinson’s therapy to roll out on NHS | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
AZ extends cardiovascular pipeline with $2bn CSPC deal | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
Novartis will appeal Entresto patent setback | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
Otsuka buys Jnana and PKU drug in $1.1bn deal | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
Pfizer rounds out haemophilia portfolio with FDA approval | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
AZ extends cardiovascular pipeline with $2bn CSPC deal | pharmaphorum

1200 x 675 · jpeg
pharmaphorum.com
Baxter medicines in short supply after hurricane hits plant | pharmaphorum
1200 x 675 · jpeg
pharmaphorum.com
AZ extends cardiovascular pipeline with $2bn CSPC deal | pharmaphorum

Some results have been hidden because they may be inaccessible to you.Show inaccessible results